CoChat

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study

Open access
van Maurik, Ingrid S, Vos, Stephanie J, Bos, Isabelle, Bouwman, Femke H, Teunissen, Charlotte E, Scheltens, Philip, Barkhof, Frederik, Frolich, Lutz, Kornhuber, Johannes, Wiltfang, Jens, Maier, Wolfgang, Peters, Oliver, Rüther, Eckart, Nobili, Flavio, Frisoni, Giovanni B, Spiru, Luiza, Freund-Levi, Yvonne, Wallin, Asa K, Hampel, Harald, Soininen, Hilkka, Tsolaki, Magda, Verhey, Frans, Kłoszewska, Iwona, Mecocci, Patrizia, Vellas, Bruno, Lovestone, Simon, Galluzzi, Samantha, Herukka, Sanna-Kaisa, Santana, Isabel, Baldeiras, Ines, de Mendonça, Alexandre, Silva, Dina, Chetelat, Gael, Egret, Stephanie, Palmqvist, Sebastian, Hansson, Oskar, Visser, Pieter Jelle, Berkhof, Johannes, van der Flier, Wiesje M · 2019 · The Lancet Neurology
Cited by 126

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND Biomarker-based risk predictions of dementia in people with mild cognitive impairment are highly relevant for care planning and to select patients for treatment when disease-modifying drugs become available. We aimed to establish robust prediction models of disease progression in people at risk of dementia. METHODS In this modelling study, we included people with mild cognitive impairment (MCI) from single-centre and multicentre cohorts in Europe and North America: the European Medical Information Framework for Alzheimer's Disease (EMIF-AD; n=883), Alzheimer's Disease Neuroimaging Initiative (ADNI; n=829), Amsterdam Dementia Cohort (ADC; n=666), and the Swedish BioFINDER study (n=233). Inclusion criteria were a baseline diagnosis of MCI, at least 6 months of follow-up, and availability of a baseline Mini-Mental State Examination (MMSE) and MRI or CSF biomarker assessment. The primary endpoint was clinical progression to any type of dementia. We evaluated performance of previously developed risk prediction models-a demographics model, a hippocampal volume model, and a CSF biomarkers model-by evaluating them across cohorts, incorporating different biomarker measurement methods, and determining prognostic performance with Harrell's C statistic. We then updated the models by re-estimating parameters with and without centre-specific effects and evaluated model calibration by comparing observed and expected survival. Finally, we constructed a model combining markers for amyloid deposition, tauopathy, and neurodegeneration (ATN), in accordance with the National Institute on Aging and Alzheimer's Association research framework. FINDINGS We included all 2611 individuals with MCI in the four cohorts, 1007 (39%) of whom progressed to dementia. The validated demographics model (Harrell's C 0·62, 95% CI 0·59-0·65), validated hippocampal volume model (0·67, 0·62-0·72), and updated CSF biomarkers model (0·72, 0·68-0·74) had adequate prognostic performance across cohorts and were well calibrated. The newly constructed ATN model had the highest performance (0·74, 0·71-0·76). INTERPRETATION We generated risk models that are robust across cohorts, which adds to their potential clinical applicability. The models could aid clinicians in the interpretation of CSF biomarker and hippocampal volume results in individuals with MCI, and help research and clinical settings to prepare for a future of precision medicine in Alzheimer's disease. Future research should focus on the clinical utility of the models, particularly if their use affects participants' understanding, emotional wellbeing, and behaviour. FUNDING ZonMW-Memorabel.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(19)30283-2

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 126

Metadata

Authors
van Maurik, I. S., Vos, S. J., Bos, I., Bouwman, F. H., Teunissen, C. E., Scheltens, P., Barkhof, F., Frolich, L., Kornhuber, J., Wiltfang, J., Maier, W., Peters, O., Rüther, E., Nobili, F., Frisoni, G. B., Spiru, L., Freund-Levi, Y., Wallin, A. K., Hampel, H., Soininen, H., Tsolaki, M., Verhey, F., Kłoszewska, I., Mecocci, P., Vellas, B., Lovestone, S., Galluzzi, S., Herukka, S.-K., Santana, I., Baldeiras, I., de Mendonça, A., Silva, D., Chetelat, G., Egret, S., Palmqvist, S., Hansson, O., Visser, P. J., Berkhof, J., & van der Flier, W. M.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2019-11
Volume
18
Issue
11
Pages
1034-1044
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2973037195
Cited by
126
References
8
FWCI
10.37
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. https://app.cochat.ai/papers/10.1016/s1474-4422(19)30283-2
The paper
van Maurik, I. S., Vos, S. J., Bos, I., Bouwman, F. H., Teunissen, C. E., Scheltens, P., Barkhof, F., Frolich, L., Kornhuber, J., Wiltfang, J., Maier, W., Peters, O., Rüther, E., Nobili, F., Frisoni, G. B., Spiru, L., Freund-Levi, Y., Wallin, A. K., Hampel, H., . . . van der Flier, W. M. (2019). Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(19)30283-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.